Trial reportScientific reports2026
Comparison of immediate therapeutic effects of 3% diquafosol and 2% rebamipide in dry eye disease: a prospective, randomized, paired-eye trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Both diquafosol and rebamipide improve signs and symptoms of dry eye disease (DED), but no clinical study has directly compared their immediate effects. This study compared the 30-min therapeutic and mucin-secreting effects of 3% diquafosol (DQS) and 2% rebamipide (REB). In this prospective, randomized, double-blinded study, 30 DED patients received DQS in one eye and REB in the fellow eye. Visual analog scale (VAS) score, tear break-up time (TBUT), ocular staining score (OSS), lipid layer thickness, corneal sensitivity, tear meniscus height, and tear levels of MUC5AC and MUC1 were measured before and 30 min after instillation. The mean age was 34.8 ± 13.8 years, and 23 patients were female. Both treatments significantly improved VAS score and TBUT at 30 min (all P < 0.05). VAS score improvement was greater with DQS than REB (P = 0.03), whereas TBUT changes were comparable (P = 0.141). Tear MUC5AC levels significantly increased after both treatments (both P ≤ 0.001), while MUC1 levels remained unchanged (P = 0.377/0.262). Changes in MUC5AC were similar between groups (P = 0.254). Overall, DQS and REB showed comparable early clinical benefits 30 min after instillation in DED, including symptom relief, improved tear film stability, and increased tear MUC5AC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.